| scholarly article | Q13442814 |
| P50 | author | Joseph R Calabrese | Q90776679 |
| P2093 | author name string | Gary S Sachs | |
| Michael D Banov | |||
| Mauricio Tohen | |||
| Holland C Detke | |||
| Charles L Bowden | |||
| James C-Y Chou | |||
| Richard Risser | |||
| Robert W Baker | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | placebo | Q269829 |
| bipolar I disorder | Q4915474 | ||
| placebo-controlled trial | Q108853737 | ||
| P304 | page(s) | 247-256 | |
| P577 | publication date | 2006-02-01 | |
| P1433 | published in | American Journal of Psychiatry | Q1935368 |
| P1476 | title | Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine | |
| P478 | volume | 163 |
| Q36653440 | A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and Co-occurring substance abuse or dependence |
| Q33543374 | A Canadian naturalistic study of a community-based cohort treated for bipolar disorder |
| Q37536783 | A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. |
| Q34260074 | A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder |
| Q34237178 | A review of bipolar disorder in adults. |
| Q36427639 | A review of the evidence for the use of antipsychotics in the maintenance treatment of bipolar disorders |
| Q56093713 | A review of valproate in psychiatric practice |
| Q35236966 | Acute and long-term treatment of mania. |
| Q34661499 | Almost all antipsychotics result in weight gain: a meta-analysis |
| Q38154852 | Alternative delivery systems for agents to treat acute agitation: progress to date |
| Q38884279 | Antipsychotic Drug-Induced Somnolence: Incidence, Mechanisms, and Management |
| Q35015469 | Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence |
| Q48258866 | Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392). |
| Q28478032 | Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature |
| Q34655996 | Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study |
| Q37970762 | Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder |
| Q36808054 | Aripiprazole: pharmacology and evidence in bipolar disorder |
| Q38077281 | Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice |
| Q36797200 | Atypical antipsychotics for the treatment of bipolar disorder: more shadows than lights |
| Q21260276 | Atypical antipsychotics in bipolar disorder: systematic review of randomised trials |
| Q38003196 | Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder |
| Q35236988 | Bipolar depression: trial-based insights to guide patient care. |
| Q33448290 | Bipolar disorder. |
| Q37219396 | Bouncing back: is the bipolar rebound phenomenon peculiar to lithium? A retrospective naturalistic study |
| Q52656684 | Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. |
| Q34809427 | Class effect of pharmacotherapy in bipolar disorder: fact or misbelief? |
| Q38167386 | Clinical and regulatory implications of active run-in phases in long-term studies for bipolar disorder. |
| Q38211511 | Clinical decision making in the treatment of mixed states |
| Q48448795 | Clinical implications of predominant polarity and the polarity index in bipolar disorder: a naturalistic study. |
| Q41574471 | Commentary on N. Ghaemi's "Hippocratic Psychopharmacology of Bipolar Disorder" Maintenance Treatment in Bipolar Disorder. |
| Q34833550 | Comparably high retention and low relapse rates in different subpopulations of bipolar patients in a German non-interventional study |
| Q38042478 | Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis |
| Q34389967 | Compliance as a stable function in the treatment course of bipolar disorder in patients stabilized on olanzapine: results from a 24-month observational study |
| Q42972743 | Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder |
| Q47756799 | Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode |
| Q45221498 | Could pramipexole induce acute mania? A case report |
| Q33414015 | Course and outcome after the first manic episode in patients with bipolar disorder: prospective 12-month data from the Systematic Treatment Optimization Program For Early Mania project |
| Q36905876 | Depot antipsychotic medications in bipolar disorder: a review of the literature |
| Q38586755 | Diagnosis, Epidemiology and Management of Mixed States in Bipolar Disorder |
| Q30583430 | Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study |
| Q42635317 | Effectiveness and weight effects of open-label lamotrigine with and without concomitant psychotropic medications in patients with bipolar I disorder. |
| Q34634154 | Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. |
| Q34197988 | Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials |
| Q48310435 | Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study |
| Q38012647 | Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry |
| Q36634257 | Emerging drugs for bipolar disorder |
| Q36881398 | Epidemiology, diagnosis and management of mixed mania |
| Q34676317 | Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology |
| Q37426143 | Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology |
| Q36762209 | Evolving trends in the long-term treatment of bipolar disorder |
| Q26824955 | Guideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders, 2012 |
| Q37813022 | Hippocratic psychopharmacology for Bipolar Disorder-An Expert's Opinion |
| Q39049252 | Is there a 'weight neutral' second-generation antipsychotic for bipolar disorder? |
| Q35822006 | Korean Medication Algorithm for Bipolar Disorder 2014: comparisons with other treatment guidelines. |
| Q64078164 | Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines |
| Q37404584 | Lithium therapy and hyperparathyroidism: an evidence-based assessment |
| Q42640514 | Lithium treatment -- moderate dose use study (LiTMUS) for bipolar disorder: rationale and design |
| Q48910862 | Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design. |
| Q36442327 | Long-term prophylaxis in bipolar disorder. |
| Q34268760 | Maintenance therapies in bipolar disorders |
| Q36902005 | Maintenance treatment in bipolar disorder: a focus on aripiprazole |
| Q37936426 | Maintenance treatment study designs in bipolar disorder: do they demonstrate that atypical neuroleptics (antipsychotics) are mood stabilizers? |
| Q35365539 | Management of bipolar depression |
| Q31088436 | Mitochondrial dysfunction as the molecular basis of bipolar disorder: therapeutic implications. |
| Q101574247 | Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials |
| Q36929705 | New approaches for the management of bipolar disorder: role of sublingual asenapine in the treatment of mania |
| Q34148283 | Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder |
| Q36427635 | Olanzapine - relapse prevention following mania |
| Q38214588 | Olanzapine discontinuation emergent recurrence in bipolar disorder. |
| Q33680103 | Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review |
| Q24241099 | Olanzapine in long-term treatment for bipolar disorder |
| Q35007923 | Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis |
| Q33673618 | Olanzapine is superior to lamotrigine in the prevention of bipolar depression: a naturalistic observational study. |
| Q37997775 | Olanzapine-induced weight gain in patients with bipolar I disorder: a meta-analysis. |
| Q37960632 | Oral ziprasidone in the treatment of patients with bipolar disorders: a critical review |
| Q38937004 | Pharmacological agents to reduce readmissions in bipolar disorder. |
| Q37219379 | Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials |
| Q36349023 | Pharmacological treatment of mixed states |
| Q41474674 | Predictors of a Shorter Time to Hospitalization in Patients with Bipolar Disorder: Medication during the Acute and Maintenance Phases and Other Clinical Factors |
| Q24643545 | Publication bias and the pharmaceutical industry: the case of lamotrigine in bipolar disorder |
| Q57244624 | Recent progress in the pharmacotherapy of bipolar disorder |
| Q100524754 | Recurrence rates in stable bipolar disorder patients after drug discontinuation v. drug maintenance: a systematic review and meta-analysis |
| Q37954423 | Refractoriness in bipolar disorder: definitions and evidence-based treatment |
| Q24657398 | Review of olanzapine in the management of bipolar disorders |
| Q37954416 | State of the art: treatment of bipolar disorders. |
| Q40262756 | Strain differences in lithium attenuation of d-amphetamine-induced hyperlocomotion: a mouse model for the genetics of clinical response to lithium |
| Q55286995 | Systematic literature review on patterns of pharmacological treatment and adherence among patients with bipolar disorder type I in the USA. |
| Q28066714 | The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm |
| Q34606256 | The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania |
| Q34649187 | The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder |
| Q37292350 | The contemporary face of bipolar illness: complex diagnostic and therapeutic challenges. |
| Q21090149 | The latest mania: selling bipolar disorder |
| Q48318194 | The medicalisation of "ups and downs": the marketing of the new bipolar disorder |
| Q37873301 | The role of ziprasidone in adjunctive use with lithium or valproate in maintenance treatment of bipolar disorder |
| Q37429721 | Treating bipolar disorder in the primary care setting: the role of aripiprazole |
| Q39048607 | Treating mixed mania/hypomania: a review and synthesis of the evidence |
| Q35203680 | Treatment implications of predominant polarity and the polarity index: a comprehensive review |
| Q39287194 | Treatment of Bipolar Disorder in a Lifetime Perspective: Is Lithium Still the Best Choice? |
| Q57730484 | Treatment of bipolar depression |
| Q36162402 | Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder |
| Q37973144 | Treatment of mixed bipolar states |
| Q44797813 | Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions? |
| Q37416878 | Trussed in evidence? Ambiguities at the interface between clinical evidence and clinical practice |
| Q35575996 | Use of a relapse monitoring board: an independent assessment for determining relapse in clinical trials for bipolar disorder. |
| Q35577365 | Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles |
| Q28281197 | The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a post hoc analysis of a double-blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Tria |
Search more.